Results: Ajanta Pharma Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

As you might know, Ajanta Pharma Limited (NSE:AJANTPHARM) just kicked off its latest first-quarter results with some very strong numbers. Ajanta Pharma beat earnings, with revenues hitting ₹16b, ahead of expectations, and statutory earnings per share outperforming analyst reckonings by a solid 17%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Following the latest results, Ajanta Pharma's 14 analysts are now forecasting revenues of ₹62.9b in 2027. This would be a meaningful 8.9% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to rise 7.6% to ₹97.82. Before this earnings report, the analysts had been forecasting revenues of ₹62.7b and earnings per share (EPS) of ₹97.86 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

View our latest analysis for Ajanta Pharma

With the analysts reconfirming their revenue and earnings forecasts, it's surprising to see that the price target rose 7.3% to ₹3,586. It looks as though they previously had some doubts over whether the business would live up to their expectations. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Ajanta Pharma at ₹4,131 per share, while the most bearish prices it at ₹2,760. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We can infer from the latest estimates that forecasts expect a continuation of Ajanta Pharma'shistorical trends, as the 12% annualised revenue growth to the end of 2027 is roughly in line with the 12% annual growth over the past five years. Juxtapose this against our data, which suggests that other companies (with analyst coverage) in the industry are forecast to see their revenues grow 12% per year. So although Ajanta Pharma is expected to maintain its revenue growth rate, it's only growing at about the rate of the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Ajanta Pharma going out to 2029, and you can see them free on our platform here.

And what about risks? Every company has them, and we've spotted 1 warning sign for Ajanta Pharma you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.